Jefferies Maintains 'Buy' Rating on Sun Pharma with ₹2,100 Target Price

Global brokerage firm Jefferies has maintained its 'Buy' rating on sun pharmaceutical with a target price of ₹2,100.00, signaling continued confidence in the pharmaceutical major's investment prospects.

Analyst Recommendation Details

The maintained 'Buy' rating from Jefferies indicates the brokerage's positive outlook on Sun Pharmaceutical Industries' business fundamentals and market position. The target price of ₹2,100.00 suggests potential upside for investors considering the stock.

Rating Parameter:	Details
Brokerage:	Jefferies
Rating:	Buy (Maintained)
Target Price:	₹2,100.00

Investment Outlook

Jefferies' decision to maintain its 'Buy' recommendation reflects the brokerage's assessment of Sun Pharmaceutical Industries' current market position and future growth potential. The target price provides investors with a benchmark for the stock's expected performance based on the analyst's evaluation of various business and market factors.

The maintained rating suggests that despite market conditions and sector dynamics, Jefferies continues to view Sun Pharmaceutical Industries as an attractive investment opportunity for portfolio consideration.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.06%	-6.70%	-7.56%	-4.76%	-9.30%	+171.21%

Sun Pharmaceutical Industries Limited has announced a board meeting scheduled for January 31, 2026, to review quarterly financial performance and consider dividend distribution to shareholders. The pharmaceutical major will deliberate on key financial matters including unaudited results and potential interim dividend declaration.

Board Meeting Agenda

The board meeting will address two primary agenda items for the company's financial review:

Agenda Item:	Details
Financial Results:	Unaudited Standalone and Consolidated Financial Results for quarter and nine months ended December 31, 2025
Dividend Consideration:	Declaration of Interim Dividend for financial year 2025-26

Interim Dividend Details

The company has established specific parameters for the potential interim dividend distribution. Key details regarding the dividend process include:

Parameter:	Information
Record Date:	February 5, 2026
Eligibility:	Equity shareholders on Register of Members as of record date
Tax Deduction:	Tax at source deduction at prescribed rates
Documentation:	Comprehensive guidance available on company website

Shareholders are advised to update their information with the depository for dematerialized shares and with MUFG Intime India Pvt. Ltd (formerly Link Intime India Pvt. Ltd.), the company's Registrar and Share Transfer Agent, for physical shares to ensure timely dividend receipt.

Trading Window Restrictions

In compliance with regulatory requirements, the company has implemented trading window restrictions during the financial results period:

Closure Date: January 1, 2026
Reopening Date: February 2, 2026
Duration: 32 days total closure period

The trading window closure aligns with SEBI regulations regarding insider trading restrictions during periods of material information disclosure.

Regulatory Compliance

The board meeting announcement has been made under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has notified both the National Stock Exchange of India Limited (NSE Code: SUNPHARMA) and BSE Limited (Stock Code: 524715) regarding the scheduled meeting and related matters.

The pharmaceutical company continues to maintain transparency in its corporate governance practices through timely disclosure of material information to stakeholders and regulatory authorities.